Insider Transactions in Q2 2022 at Biocryst Pharmaceuticals Inc (BCRX)
Insider Transaction List (Q2 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 07
2022
|
Steve Aselage Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,866
+21.64%
|
-
|
|
Jun 07
2022
|
Steven K Galson Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,866
+50.0%
|
-
|
|
Jun 07
2022
|
Kenneth B Lee Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,866
+25.74%
|
-
|
|
Jun 07
2022
|
Alan G Levin Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,866
+44.47%
|
-
|
|
Jun 07
2022
|
George B Abercrombie Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,866
+50.0%
|
-
|
|
Jun 07
2022
|
Theresa Heggie Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,866
+29.86%
|
-
|
|
Jun 07
2022
|
Amy E Mc Kee Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,866
+50.0%
|
-
|
|
Jun 07
2022
|
Nancy J Hutson Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,866
+14.17%
|
-
|
|
Jun 07
2022
|
Robert Alexander Ingram Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,866
+11.93%
|
-
|
|
Jun 07
2022
|
Vincent Milano Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,866
+29.76%
|
-
|
|
Jun 07
2022
|
Machelle Sanders Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,866
+50.0%
|
-
|
|
May 31
2022
|
Robert Alexander Ingram Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,078
+2.47%
|
$18,702
$9.31 P/Share
|
|
May 31
2022
|
Alan G Levin Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,138
+26.25%
|
$10,242
$9.31 P/Share
|
|
May 31
2022
|
Theresa Heggie Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,138
+6.15%
|
$10,242
$9.31 P/Share
|
|
May 31
2022
|
Steve Aselage Director |
BUY
Grant, award, or other acquisition
|
Direct |
569
+1.66%
|
$5,121
$9.31 P/Share
|
|
Apr 18
2022
|
George B Abercrombie Director |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$55,000
$11.04 P/Share
|
|
Apr 18
2022
|
George B Abercrombie Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$15,000
$3.32 P/Share
|
|
Apr 01
2022
|
Helen M. Thackray Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
7,600
-5.28%
|
$121,600
$16.2 P/Share
|